Researchers have discovered a way in which to sensitize drug-resistant human glioblastoma cells to chemotherapy.
Administering the chemotherapy drug temozolomide to glioblastoma brain cancer patients in the morning may enhance the cancer-fighting effects. The study demonstrates the timing of chemotherapy could have a significant impact on treatment for glioblastoma patients.
Researchers have discovered a biomarker which predicts whether glioblastoma brain tumors will respond to chemotherapy.
A new drug has been cleared for human trials in patients with anaplastic astrocytoma and glioblastoma brain cancers. The drug, PAC-1, is reported to spur cancer cells to self destruct and has proven to be effective in animal models of brain cancers.
Temozolomide, a chemotherapy drug used to treat brain cancer, could increase risks of developing depression by preventing neurogenesis, a new study reports.
A new study argues that prolonged chemotherapy decreases the development of new brain cells, and disrupts ongoing brain rhythms in the part of the brain responsible for making new memories.
Researchers at MIT have developed a new drug delivering nanoparticle that is able to cross the blood-brain barrier. The nanoparticles carry two different drugs that can help shrink tumors and prevent them from growing back.
Researchers suggest delivering chemotherapy directly into the brain cavity could offer a better way to treat tumors which have metastasized to the brain.
Researchers report our gender can determine longevity and response to treatment for glioblastoma brain cancer. The study reports male survival is determined by genes that control cell division, where as female survival is often determine by genes that regulate the ability of cancer cells to migrate to different brain areas.
When aggressive, malignant tumors appear in more than one location in the brain, patient survival tends to be significantly shorter than when the disease starts as a single tumor, even though patients in both groups undergo virtually identical treatments, according to research at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Research Institute.
Glioblastmoa brain cancer patients who received an experimental vaccines in combination with chemotherapy showed improved suitability and tolerated the treatment well, a new study reports.
Recurrent gliomas could have genetic profiles which are different from those of the initial tumors that spawned them, a new study reports.
